Welcome to our dedicated page for Abcellera Biologics SEC filings (Ticker: ABCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing hundreds of pages on antibody discovery breakthroughs, partner milestones, and evolving clinical data in AbCellera’s filings can be overwhelming. When a science-driven company like AbCellera Biologics Inc. reports multi-year R&D commitments or receives a big milestone payment, the disclosure is buried deep inside a 10-K. Stock Titan resolves that frustration by converting dense biotech language into plain English summaries you can act on.
Whether you need the latest AbCellera quarterly earnings report 10-Q filing, an 8-K material events explained alert, or AbCellera insider trading Form 4 transactions, our platform delivers every document as soon as it hits EDGAR—plus an AI-powered overview that highlights cash runway, pipeline updates, and collaboration revenue in minutes. Skip scrolls and find: revenue trends, R&D burn, milestone receivables, and AbCellera executive stock transactions Form 4 without hunting through footnotes.
Here’s how investors use these insights:
- Track insider confidence via AbCellera Form 4 insider transactions real-time.
- Compare drug candidate progress quarter-over-quarter with AI charts drawn from each 10-Q.
- Quickly review compensation shifts in the AbCellera proxy statement executive compensation.
- Assess material collaborations the moment a new 8-K posts.
From an AbCellera annual report 10-K simplified narrative to an AbCellera earnings report filing analysis, Stock Titan keeps every stakeholder understanding AbCellera SEC documents with AI. Real-time updates, complete coverage, and approachable explanations mean less time reading and more time deciding.
AbCellera Biologics Inc. (ABCL) reported an insider share purchase by a company director. On 11/26/2025, the reporting person bought 50,000 common shares in an open market transaction coded as "P" at a price of $3.5692 per share. After this transaction, the director beneficially owned 221,000 common shares directly.
The filing also notes indirect ownership of an additional 5,000 common shares held by the director’s spouse. The form is filed as a Form 4 for one reporting person and indicates the director relationship to AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) announced Board changes. On November 10, 2025, the Board appointed Stephen Quake, D.Phil., as a director, effective immediately. He will serve until the next annual meeting and has been deemed independent under Nasdaq rules and the Company’s guidelines. Dr. Quake was assigned to the Audit Committee and the Nominating and Corporate Governance Committee and will participate in the Non-Employee Director Compensation Policy on the same terms as other non-employee directors.
Also on November 10, 2025, Andrew Lo, Ph.D., resigned from the Board, effective immediately. The Company stated his resignation was not due to any disagreement. He previously served on the Audit and Nominating and Corporate Governance Committees.
AbCellera Biologics (ABCL) reported a wider quarterly loss while progressing its first proprietary programs into the clinic. For the quarter ended September 30, 2025, revenue was $8.955 million, driven mainly by research fees. Net loss was $57.119 million, or $0.19 per share. For the first nine months of 2025, revenue reached $30.275 million and net loss totaled $137.467 million.
Total cash, cash equivalents, and marketable securities were $495.672 million as of September 30, 2025, compared with $625.614 million at December 31, 2024. Operating expenses fell year over year due to the absence of 2024 impairment charges, though research and development rose to $55.028 million in the quarter as the company advanced internal programs and began clinical activities. AbCellera initiated Phase 1 trials in the second half of 2025 for ABCL635 (vasomotor symptoms) and ABCL575 (OX40L antibody for inflammation) after receiving Health Canada No Objection Letters in May. The company reported 103 partner-initiated programs with downstream participation and 18 molecules in the clinic. Common shares outstanding were 299,335,048 as of November 3, 2025.
AbCellera Biologics Inc. (ABCL) furnished a press release and investor presentation related to its financial and operational results for the quarter ended September 30, 2025. The company aligned the materials with its earnings call on November 6, 2025, and provided them as exhibits.
The information under Items 2.02 and 7.01 is being furnished, not filed, and is not subject to Section 18 liability nor incorporated by reference except as stated. Exhibits include 99.1 (press release) and 99.2 (corporate presentation).
FAQ
What is the current stock price of Abcellera Biologics (ABCL)?
What is the market cap of Abcellera Biologics (ABCL)?
